George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 634.00
Bid: 632.00
Ask: 633.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.158%)
Open: 642.50
High: 642.50
Low: 630.00
Prev. Close: 634.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

26 Oct 2016 10:17

26 October 2016

Tate & Lyle PLC

Board changes

Tate & Lyle PLC (the “Company”) announces that Jeanne Johns has been appointed as a Non-Executive Director and a member of the Corporate Responsibility, Remuneration and Nominations Committees with effect from today, 26 October 2016.

Jeanne is based in the US and is a non-executive director of Parsons Corporation, a US engineering, construction, technical, and management services organisation. During Jeanne’s 30 year career with BP, she most recently served as the Head of Safety and Operational Risk for BP’s global downstream business from 2011 to 2015 and was responsible for overhauling the safety and operational risk organisation. Prior to this role, Jeanne held numerous leadership roles in Europe, the US and China, managing multinational businesses and global strategic business development.

Jeanne will assume the chairmanship of the Corporate Responsibility Committee with effect from 1 April 2017. She will replace Bill Camp who is retiring as a Director of the Company on 31 March 2017, having served on the Board since May 2010.

Sir Peter Gershon, Chairman of Tate & Lyle, said "I am delighted that Jeanne has agreed to join the Board. Her significant experience of building organisational cultures with the highest standards in safety, together with her experience in a range of global leadership roles will be of significant benefit to the Board.

“I would also like to thank Bill for his dedicated service and the significant contribution he has made to the Board and the Corporate Responsibility Committee during his tenure.”

There are no further disclosures to be made in connection with Ms Johns’s appointment pursuant to paragraph 9.6.13 of the Financial Conduct Authority’s Listing Rules.

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 25 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2016, Tate & Lyle sales totalled £2.4 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161026005652/en/

Copyright Business Wire 2016

Date   Source Headline
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares
10th Aug 20222:15 pmRNSDirector/PDMR Shareholding
4th Aug 20223:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20224:00 pmRNSHolding(s) in Company
28th Jul 20221:00 pmRNSUpdate on Preference Share Reduction Timetable
28th Jul 202212:45 pmRNSResult of AGM
15th Jul 20225:20 pmRNSDirector/PDMR Shareholding
1st Jul 202210:45 amRNSBlock listing Interim Review
1st Jul 202210:17 amRNSTotal Voting Rights
29th Jun 20224:25 pmRNSDirector/PDMR Shareholding
29th Jun 20224:00 pmRNSDirector/PDMR Shareholding
24th Jun 20224:15 pmRNSHolding(s) in Company
23rd Jun 20223:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.